The incidence of type 2 diabetes mellitus is increasing due to changing life-styles. Today the slogan of all diabetologists is "strict glycaemic control" to prevent long term diabetic complications. The traditional agents- sulphonylureas, biguanides and insulin sometimes fail to achieve the recommended goal. However, newer insulin secretagogues (glimepiride, repaglinide, glucagan like peptide-1 agonists), drugs decreasing insulin resistance (thiazolidinediones), agents slowing carbohydrate absorption (miglitol, amylin analogues) and newer insulins (insulin lispro) have been developed for the management of type 2 diabetes mellitus. With the advent of these newer drugs, management of type 2 diabetes promises to scale new heights in the new millennium.

This content is only available via PDF.
You do not currently have access to this content.